Therapeutic Asset Ratings

329 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Anti-Bcma Car-T Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P2	CCC (54)
Bcma-Gprc5D Car-T Cells Plasma Cell Myeloma	Donghua Zhang	P2	CCC (54)
Treosulfan Plasma Cell Myeloma	Insel Gruppe AG, University Hospital Bern	P2	CCC (54)
AUTOLOGOUS PERIPHERAL BLOOD MONONUCLEAR CELL (PBMC)-DERIVED T LYMPHOCYTES TRANSDUCED EX VIVO WITH A NON-REPLICATING, SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR ENCODINGA CHIMERIC ANTIGEN RECEPTOR (CAR) TARGETING TWO EPITOPES OF THE HUMAN B CELL MATURATION ANTIGEN (BCMA) UNDER THE CONTROL OF A HUMAN ELONGATION FACTOR 1 ALPHA (EF1.ALPHA.) PROMOTER THE CODING SEQUENCE COMPRISES A HUMAN CD8 ALPHA SIGNAL PEPTIDE (CD8.ALPHA. SP), A BCMA TARGETING DOMAIN CONSISTING OF TWO VARIABLE HEAVY CHAIN-ONLY ANTIBODIES (VHH1 AND VHH2) TARGETING TWO DISTINCT BCMA EPITOPES, A HUMAN CD8 ALPHA HINGE AND TRANSMEMBRANE DOMAIN (CD8.ALPHA. HINGE + TM), A HUMAN CD137 CYTOPLASMIC DOMAIN (4-1BB) AND A HUMAN CD3 ZETA CYTOPLASMIC DOMAIN (CD3.ZETA.). THE VECTOR GENOME CONTAINS A CHIMERIC ROUS SARCOMA VIRUS (RSV)/TRUNCATED 5'LTR AND A SELF-INACTIVATING 3'LTR-SIN (.DELTA.-U3) Plasma Cell Myeloma	Janssen Research & Development, LLC	P2	CCC (53)
Dc/Mm Fusion Vaccine Plasma Cell Myeloma	David Avigan	P2	CCC (53)
Marizomib Plasma Cell Myeloma	Dana-Farber Cancer Institute	P2	CCC (53)
Palbociclib Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (53)
TRASTUZUMAB Plasma Cell Myeloma	OHSU Knight Cancer Institute	P2	CCC (53)
PROPRANOLOL Plasma Cell Myeloma	GPCR Therapeutics, Inc.	P2	CCC (52)
allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines. Plasma Cell Myeloma	David Wald	P1/2	CCC (52)
Bcma-Cart Cells Plasma Cell Myeloma	Institute of Hematology & Blood Diseases Hospital, China	P1/2	CCC (52)
Dabrafenib Plasma Cell Myeloma	Cancer Research UK	P2/3	CCC (52)
Forimtamig Plasma Cell Myeloma	Hoffmann-La Roche	P1/2	CCC (52)
Bcd-264 Plasma Cell Myeloma	Biocad	P3	CCC (50)
COLCHICINUM Plasma Cell Myeloma	Affiliated Hospital of Nantong University	P3	CCC (50)
Equecabtagene Autoleucel Plasma Cell Myeloma	Nanjing IASO Biotechnology Co., Ltd.	P3	CCC (50)
Grastofil Plasma Cell Myeloma	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	P3	CCC (50)
Idecabtagene Vicleucel Plasma Cell Myeloma	St. Olavs Hospital	P3	CCC (50)
Lapelga Plasma Cell Myeloma	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	P3	CCC (50)
Moderna Bivalent Mrna Vaccine Plasma Cell Myeloma	Monash University	P3	CCC (50)
Narlumosbart Plasma Cell Myeloma	RenJi Hospital	P3	CCC (50)
Olanzapine Plasma Cell Myeloma	The Affiliated People's Hospital of Ningbo University	P3	CCC (50)
OXYCODONE HYDROCHLORIDE, HYDROCODONE- Plasma Cell Myeloma	St. Louis University	P3	CCC (50)
Pfizer Bivalent Covid-19 Vaccine Plasma Cell Myeloma	Monash University	P3	CCC (50)
Tropisetron Plasma Cell Myeloma	The Affiliated People's Hospital of Ningbo University	P3	CCC (50)

Showing 101 to 125 of 329 assets

PreviousPage 5 of 14Next